心血管、肾脏与代谢健康:心力衰竭预防的可行动愿景
文章指出心力衰竭是全球可预防住院的首要原因且患病率持续增长,流行病学研究显示其他心血管疾病及肾脏与代谢功能障碍日益促进心衰发生,临床试验证明多种新药物疗法可同时改善心血管、肾脏与代谢(CKM)健康,提出将心衰预防置于CKM健康框架下具有可操作性。
要点
- 心力衰竭是全球可预防住院的首要原因,患病率显著且持续增长。
- 其他心血管疾病及肾脏与代谢功能障碍日益参与心衰发生。
- 多种新药物疗法可同时改善心血管、肾脏与代谢健康。
核心结论
- 将心力衰竭预防置于心血管、肾脏与代谢健康的更广泛背景下,为患者、卫生专业人员、卫生系统、社区和政策制定者提供了可行动的框架。
研究设计与样本
- 本文为综述,汇总流行病学研究和临床试验证据,阐述心血管、肾脏与代谢健康与心力衰竭预防的关系。
主要发现
- 流行病学研究表明其他形式的心血管疾病以及肾脏和代谢功能障碍频繁且日益促进心力衰竭发生。
- 临床试验表明多种新药物疗法能够同时改善心血管、肾脏与代谢健康。
临床怎么用
- 作者提出将心力衰竭预防定位在心血管、肾脏与代谢健康的 broader 背景下,形成可行动框架,面向患者、卫生专业人员、卫生系统、社区和政策制定者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The substantial and growing prevalence of heart failure, which remains the leading cause of preventable hospitalisation worldwide, has brought heart failure prevention into sharp focus. Although this condition has historically been characterised by impaired cardiac function, mounting evidence has underscored its complex and multisystem pathobiology. Epidemiological studies have indicated that other forms of cardiovascular disease, along with kidney and metabolic dysfunction, frequently and increasingly contribute to heart failure onset. Clinical trials have additionally demonstrated the power of several new pharmacotherapies to simultaneously modify cardiovascular, kidney, and metabolic (CKM) health. This convergence of epidemiology and therapy highlights deeply interconnected mechanisms of disease, identifying CKM diseases-and their pathophysiological and sociostructural antecedents-as important but often under-recognised targets for heart failure prevention. Herein, we illustrate that positioning heart failure prevention within the broader context of CKM health provides an actionable framework for patients, health-care professionals, health systems, communities, and policy makers.
引用
- Ostrominski JW, Cheng AYY, Nelson AJ, et al. Cardiovascular, kidney, and metabolic health: an actionable vision for heart failure prevention. Lancet. 2025. PMID: 40889511. doi:10.1016/S0140-6736(25)01384-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。